title: NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma.
abstract: NT-proBNP provides diagnostic and prognostic information in heart syndromes but its role in cancer has not yet been established. The prognostic value of NT-proBNP was prospectively studied in 104 non-Hodgkin lymphoma (NHL) patients treated with chemotherapy. Echocardiography and NT-proBNP were determined prior to treatment. In multivariate analysis, NT-proBNP ≥ 900 pg/ml was the variable with higher risk of death (adjusted hazard ratio 11.1; 95% CI 3.8-32.9; P<0.001). The C statistic for NT-proBNP ≥ 900 pg/ml was significantly better than IPI score for prediction of survival. These findings suggest that NT-proBNP ≥ 900 pg/ml could be considered a useful marker for risk assessment in NHL patients treated with chemotherapy.
authors.affiliation: Department of Clinical Hematology, Hospital Universitari del Mar, Barcelona, Spain. 94015@hospitaldelmar.cat
authors.forename: Eva
authors.initials: E
authors.lastname: Gimeno
authors.forename: Miquel
authors.initials: M
authors.lastname: Gómez
authors.forename: Juan Ramón
authors.initials: JR
authors.lastname: González
authors.forename: Josep
authors.initials: J
authors.lastname: Comín
authors.forename: Alberto
authors.initials: A
authors.lastname: Alvarez-Larrán
authors.forename: Blanca
authors.initials: B
authors.lastname: Sánchez-González
authors.forename: Lluis
authors.initials: L
authors.lastname: Molina
authors.forename: Eva
authors.initials: E
authors.lastname: Domingo-Domenech
authors.forename: Francesc
authors.initials: F
authors.lastname: Garcia-Pallarols
authors.forename: Carmen
authors.initials: C
authors.lastname: Pedro
authors.forename: Eugenia
authors.initials: E
authors.lastname: Abella
authors.forename: Carles
authors.initials: C
authors.lastname: Vilaplana
authors.forename: Silvia
authors.initials: S
authors.lastname: de Sanjosé
authors.forename: Carlos
authors.initials: C
authors.lastname: Besses
authors.forename: Antonio
authors.initials: A
authors.lastname: Salar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis*; D004452:Echocardiography; D005260:Female; D006331:Heart Diseases / Q000175:diagnosis*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020097:Natriuretic Peptide, Brain / Q000032:analysis*; D010446:Peptide Fragments / Q000032:analysis*; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain